Dive Brief:An experimental heart drug from biotechnology company NewAmsterdam Pharma met its main goal in the first of several Phase 3 trials, but the results fell short of investor and analyst expectations.In the trial, people with an inherited condition called heterozygous familial hypercholesterolemia who received the drug alongside other medicines saw their levels of LDL, or bad, cholesterol fall by 36% after three months, when adjusted for placebo, and by 41% after one year. The drug, obicetrapib, reduced other markers of heart disease while its safety was comparable to placebo, the company said.On a conference call, NewAmsterdam CEO Michael Davidson said the results raise the companys confidence in other ongoing studies. But shares fell by as much as one-third in premarket trading before opening down 4% Monday morning, as investors had anticipated more powerful cholesterol-lowering effects.Dive Insight:NewAmsterdams study is part of the biotechs effort to change the narrative surrounding a class of heart drugs known as CETP inhibitors.These drugs were once seen as a possible breakthrough in heart medicine, as companies bet that raising high-density lipoprotein, or HDL, could have stronger effects than reducing the LDL cholesterol associated with heart problems.Poor clinical performance and safety concerns caused several pharmaceutical companies to abandon research, however. Among them was Amgen, which had picked up obicetrapib in a 2015 acquisition of biotech Dezima but suspended development shortly after.Amgens decision created an opportunity for NewAmsterdam, which was launched by Dezima founders in 2019 and licensed obicetrapib from Amgen a year later. The company claims obicetrapib may be more potent and safer than previous CETP inhibitors. Early- and mid-stage studies showed promise, with the drug safely raising HDL as well as lowering LDL cholesterol. Four late-stage trials are now underway and, ahead of the results, some analysts predicted the drug could become a blockbuster if successful.Yet myriad other therapies, among them generic statins and potent, injectable drugs called PCSK9 inhibitors, are available to lower cholesterol. PCSK9 blockers can reduce LDL levels by about 50% to 60% in heterozygous familial hypercholesterolemia patients and even they havent met analysts once-lofty financial projections. Jefferies Dennis Ding, in a Friday note to clients, wrote that investors were generally looking for obicetrapib treatment to lead to at least a 40% difference in LDL levels after three months, a mark it missed.NewAmsterdam executives claimed the results show the consistency of obicetrapibs effects. They noted how the drugs LDL-C lowering appeared to strengthen with time, which could bode well for a longer, ongoing study designed to test whether obicetrapib can reduce the risk of cardiovascular events. They also highlighted the drugs safety, noting that, in the study, a higher percentage of placebo recipients discontinued treatment. Trial investigators also didnt observe the types of side effects seen in testing of other CETP inhibitors.This was a very, very well tolerated drug, and that, to me, at the end of the day, is going to be a big part of our story for clinicians and for patients, said Davidson, on a conference call.Jefferies analyst Ding also defended the findings, writing Monday that the few percentage points difference in LDL reduction versus expectations isnt overly relevant given placebo recipients initially overperformed and the drugs effects improved.NewAmsterdam will present detailed results at a medical meeting in November. Meanwhile, a study in people with atherosclerotic cardiovascular disease, a more common heart condition, will read out results by the end of the year. '